ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 322

Reduction of Treatment Needed for Knee Osteoarthritis after Bariatric Surgery

Evan Wilder1, Janice Lin1, Fernando Bomfim1, Thayer Mukherjee1, Lucy O'Shaughnessy1, Lauren Browne1, Myriam Weill1, Kevin Gernavage1, Farah Taufiq1, Renata La Rocca Vieira2, Christine Ren-Fielding3, Manish Parikh4, Steven B. Abramson5 and Jonathan Samuels6, 1NYU Langone Medical Center, New York, NY, 2Department of Radiology, NYU Langone Medical Center, New York, NY, 3Department of Surgery, New York University School of Medicine, New York, NY, 4Department of Surgery, NYU Langone Medical Center, New York, NY, 5Dept of Rheumatology/Medicine, Hosp for Joint Diseases/NYU, New York, NY, 6Rheumatology, NYU - Hospital for Joint Diseases, New York, NY

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Knee, Osteoarthritis, treatment and weight loss

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Osteoarthritis - Clinical Aspects Poster I: Treatments and Metabolic Risk Factors

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  Medical treatment for knee osteoarthritis (KOA) can be limited and risk morbidity. Weight loss reduces the arthritis burden and may preclude aggressive treatment. Bariatric surgery trumps diet/exercise for sustainable weight loss; studies suggest improvement in KOA pain long after surgery. We prospectively evaluate the prevalence of painful KOA in obesity and track the effect of bariatrics on knee pain and function. Our hypothesis is that successful weight loss surgery decreases the need for KOA management.

Methods: We screened patients prior to bariatric surgery, targeting knee pain for ≥1 month and a visual analog scale pain ≥30mm. We excluded those with lupus, inflammatory arthritis, psoriasis, or bilateral total knee replacements. Pre-op assessments included BMI, Radiographic severity by Kellgren-Lawrence (KL) grade, questionnaires for knee pain/function (i.e. Knee Injury and Osteoarthritis Outcome Score), and an inventory of KOA treatment – including visits to musculoskeletal subspecialists, medication (oral/topical/intraarticular) and physical therapy. We reassessed patients at 1, 3, 6 and 12 months post surgery, also calculating percent excess weight loss (%EWL).

Results:  Of 536 patients considering bariatric surgery, we found 308 with knee pain and enrolled 176 (91.5% female; mean BMI 43.6 kg/m2±7, range 32-61; mean age 42 ±11, range 18-73). Radiographic severity was well distributed (KL0-KL4). Higher KL grade and BMI correlated with worse pre-op symptoms (data not shown). Patients with worse baseline KL scores visited specialists more often (KL0=33% vs KL3-4=72%, p=0.001) and were more likely to use at least one prescribed treatment (KL0=19% vs KL3-4=57%, p=0.001).

            For the 150 patients who completed bariatric surgery, average knee pain and function improved at each post-operative interval, correlating with %EWL sustained over time (data not shown). We found a marked decrease in treatment used at the intervals, including the 6 month followup. The percent of patients using over the counter analgesics dropped from 87.5% to 47.2% (p<0.0001), visits to specialists fell from 55.7% to 24.7% (p<0.0001), and patients needing the various prescribed treatments decreased from 40.3% to 12.4% (p<0.0001).

            While the attenuated need for KOA treatment trended with %EWL, those with post-op BMI >40 had an increased need for knee specialists – up from 33.3% to 71.4% (post-op month 1 to 12) with a pre-op baseline 53.8%. Conversely, specialist visits for patients with a BMI <40 only rose from 26.8% to 28.6% with a pre-op baseline of 58.6%. Prescription KOA treatment in the post-op BMI>40 group also rose from 11.1% to 43% (post-op month 1 to 12) from pre-op baseline 38.7%, while those patients remaining under a BMI of 40 saw their use of prescription KOA treatment fall from 17.1% to 14.3% with pre-op baseline 42.9%.  

Conclusion: The improvement in KOA symptoms from bariatric weight loss is reflected by a significantly decreased need for treatment. This reduction is sustained over time except in the patients whose BMI remains above 40.  While radiographic severity correlates with patients’ treatment patterns at baseline, it does not appear to limit their ability to decrease knee treatment with successful weight loss surgery.


Disclosure: E. Wilder, None; J. Lin, None; F. Bomfim, None; T. Mukherjee, None; L. O'Shaughnessy, None; L. Browne, None; M. Weill, None; K. Gernavage, None; F. Taufiq, None; R. La Rocca Vieira, None; C. Ren-Fielding, Apollo Endosurgery, 5; M. Parikh, None; S. B. Abramson, None; J. Samuels, None.

To cite this abstract in AMA style:

Wilder E, Lin J, Bomfim F, Mukherjee T, O'Shaughnessy L, Browne L, Weill M, Gernavage K, Taufiq F, La Rocca Vieira R, Ren-Fielding C, Parikh M, Abramson SB, Samuels J. Reduction of Treatment Needed for Knee Osteoarthritis after Bariatric Surgery [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/reduction-of-treatment-needed-for-knee-osteoarthritis-after-bariatric-surgery/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reduction-of-treatment-needed-for-knee-osteoarthritis-after-bariatric-surgery/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology